Renjith Vijayakumar Selvarani, Founder, Chairman, Chief Scientific and Technology Officer at OLUSIUM, shared on LinkedIn:
“Researchers created DNA-based nanorobots that selectively target and destroy cancer cells while leaving healthy tissues completely untouched.
In a groundbreaking advancement for nanomedicine, researchers at the Karolinska Institutet in Stockholm have developed innovative DNA-based nanorobots capable of targeting and destroying cancer cells with unprecedented precision. Utilizing a cutting-edge technique known as ‘DNA origami,’ the scientists built a microscopic delivery vehicle that conceals a lethal peptide weapon, preventing it from interacting with healthy tissue.
This weapon is only exposed and activated when it encounters the acidic, low-pH microenvironment characteristic of solid tumors. This ingenious ‘kill switch’ ensures that the cancer-fighting agents are deployed strictly where they are needed, leaving normal cells completely unharmed.
When tested in animal models, the pH-responsive nanorobots successfully reduced breast cancer tumor growth by up to 70 percent compared to control groups. Because typical healthy tissue maintains a neutral pH of 7.4, keeping the nanorobot’s weapon folded and inactive, the surrounding healthy cells remain completely undamaged. While further trials are necessary to confirm safety, toxicity, and efficacy in humans, this milestone represents a monumental leap forward in oncology, offering a future where cancer treatments no longer rely on devastating, body-wide side effects.”
Title: A DNA robotic switch with regulated autonomous display of cytotoxic ligand nanopatterns
Authors: Yang Wang, Igor Baars, Ieva Berzina, Iris Rocamonde-Lago, Boxuan Shen, Yunshi Yang, Marco Lolaico, Janine Waldvogel, Ioanna Smyrlaki, Keying Zhu, Robert A. Harris, Björn Högberg
You can read the Full Article in Nature Nanotechnology.
You can also read:
ASCO Updates Breast Cancer Follow-Up Guidelines With Risk-Based Surveillance Approach